Gut Microbiota Influence on Parkinson's Disease Mechanisms

Parkinson’s disease is increasingly recognised as a multisystem disorder in which the gut microbiota exerts pivotal influences on disease initiation and progression. The trillions of micro-organisms resident in the gastrointestinal tract engage in bidirectional communication with the central nervous system via neural, immune and metabolic pathways collectively termed the microbiota-gut-brain axis. Dysbiosis within this community can compromise intestinal barrier integrity, trigger systemic and neuro-inflammation, modulate α-synuclein misfolding and influence levodopa metabolism. Alterations in short-chain fatty acid production and endotoxin levels appear to shape microglial activation and neuronal survival in the substantia nigra. Growing evidence from clinical and preclinical studies highlights the potential for microbial signatures as early biomarkers and for microbiota-targeted interventions—ranging from dietary modulation and probiotics to faecal microbiota transplantation—to modify disease trajectory and ameliorate motor and non-motor phenotypes.

Research from Nature Portfolio

Recent studies have delineated prodromal changes in gut microbial composition and functional capacity. Work profiling early-stage Parkinson’s disease, rapid eye movement sleep behaviour disorder and at-risk relatives revealed progressive loss of butyrate-producing taxa and enrichment of pro-inflammatory Collinsella, detectable before overt motor symptoms. Investigations into microbial drug metabolism identified gut bacterial tyrosine decarboxylases that convert therapeutic levodopa to dopamine in the proximal small intestine, thereby reducing systemic drug availability and necessitating higher dosing in some patients. Mechanistic experiments using bacterial amyloid-producing strains demonstrated that curli proteins can cross-seed host α-synuclein aggregation and prime innate immune responses, underpinning a potential route for microbiota-driven synucleinopathy.

Gut Microbiota Influence on Parkinson's Disease Mechanisms publication trend

The graph below shows the total number of articles in gut microbiota influence on parkinson's disease mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha-synuclein: A neuronal protein prone to misfolding and aggregation, forming Lewy bodies that characterise Parkinson’s disease pathology.

Microbiota-gut-brain axis: The network of biochemical signalling pathways linking gut microbial communities with central nervous system function.

Short-chain fatty acids: Microbial fermentation products (e.g. acetate, propionate, butyrate) that influence gut barrier integrity, immune responses and neuronal health.

Lipopolysaccharide-TLR4 signalling: An immune activation pathway initiated by bacterial endotoxin binding to Toll-like receptor 4, driving inflammatory cascades.

Tyrosine decarboxylase: A microbial enzyme that converts tyrosine and structurally similar compounds such as levodopa into decarboxylated products, impacting drug bioavailability.

References

1. Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease. Molecular Neurodegeneration (2023).
2. Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Nature Communications (2023).
3. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. npj Parkinson's Disease (2021).
4. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nature Communications (2019).
5. Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome (2021).
6. Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Scientific Reports (2016).